Breaking News

Batavia Biosciences Expands HQ and R&D Services

Increases capacity for viral vectors and vaccine R&D in Netherlands.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Batavia Biosciences has unveiled plans for the expansion of its headquarters and R&D capacities in the Netherlands by adding 22,500 square feet to its infrastructure. The expansion allows the company to increase its R&D activities for viral vector-based product development including Lentivirus, AAV, Adenovirus, and Measles virus vectors. In addition, the increased R&D infrastructure helps to meet increased global demand for vaccine development, be it live-attenuated, whole killed, ve...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters